Abera appoints Maria Alriksson as new CEO for the company from mid-October 2020. She replaces Anders Ericson who has been CEO since 2015 in parallel to his responsibility as Chairman of the Board.
Maria Alriksson held the position as CEO in Xbrane Biopharma at the time when the vaccine development business, now Abera Bioscience, was spun out 2012. She now comes from a position as senior consultant within strategy and business development.
“With Maria Alriksson on board, Abera gets a CEO who is an experienced leader and also very familiar with Abera’s business. Maria joins the company in a very exciting phase, right at the crossroads between research and commercial development. Her background, drive and skills will be very valuable to Abera. So far, more than 100 million SEK has been invested in the vaccine platform, mostly through soft money. The interest in our platform has increased in recent years and our technology is included, for example, in three different external preclinical covid-19 vaccines”, says Anders Ericson, Chairman of the Board.
“Abera is an incredibly exciting company with solid technology and I look forward to being a part of taking it to the next level. The current pandemic has further demonstrated the ever-increasing need for vaccines in general and quick response platforms in particular. It feels inspiring to, with the help of innovative technology, get the chance to actually save millions of lives”, says the new CEO Maria Alriksson.